Clascoterone
PharmaceuticalPreclinicalAlso known as: Winlevi, Cortexolone 17alpha-propionate, CB-03-01, Breezula, 17alpha-propionyl cortexolone
Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. Food and Drug Administration in August 2020 for the treatment of acne vulgaris in patients 12 years of age and older.
Overview
At A Glance
Clascoterone's mechanism of action is competitive antagonism of androgen receptors (AR) in cutaneous target tissues — specifically the sebocytes of sebaceous glands and the dermal papilla cells of hair follicles — combined with rapid systemic hydrolysis to the inactive metabolite…
Mechanism of Action
Clascoterone's mechanism of action is competitive antagonism of androgen receptors (AR) in cutaneous target tissues — specifically the sebocytes of sebaceous glands and the dermal papilla cells of hair follicles — combined with rapid systemic hydrolysis to the inactive metabolite cortexolone upon absorption, resulting in potent local anti-androgenic activity with minimal systemic exposure to active compound. This pharmacology is conceptually simple but pharmaceutically elegant: clascoterone is an ester prodrug (cortexolone 17α-propionate) with high lipid-solubility and good skin-penetration properties, allowing it to reach target cutaneous tissues at therapeutically meaningful concentrations; once it enters systemic circulation, plasma esterases rapidly cleave the propionate ester to yield cortexolone, which has weak AR-binding activity and is further metabolized and cleared. The result is an agent that behaves like a potent local AR antagonist at the site of application but like an essentially inactive compound systemically — the therapeutic separation between local effect and systemic exposure that had long been sought for antiandrogen dermatology.
1. Androgen receptor competitive antagonism — the primary mechanism. Clascoterone (cortexolone 17α-propionate) binds to the androgen receptor in a competitive fashion, displacing endogenous ligands testosterone and dihydrotestosterone (DHT) from the receptor's ligand-binding domain. Binding affinity studies using isolated AR and cell-based transactivation assays have shown clascoterone to have binding affinity in the nanomolar range — comparable to or somewhat greater than DHT itself at certain assay conditions. Mechanism of antagonism: clascoterone binding to AR prevents the receptor from adopting the active conformation required for (a) dissociation from heat-shock chaperone proteins, (b) nuclear translocation, (c) dimerization, and (d) binding to androgen response elements (ARE) in DNA. The net effect is blockade of androgen-mediated gene transcription in target tissues. This is conceptually similar to other nonsteroidal AR antagonists (flutamide, bicalutamide, enzalutamide) but delivered topically with rapid systemic inactivation, giving site-specific activity.
2. Sebocyte-specific AR blockade and sebum reduction. Sebaceous glands contain high densities of androgen receptors; sebogenesis is tightly androgen-dependent. DHT binding to sebocyte AR stimulates sebocyte proliferation, differentiation, and lipid synthesis, producing the sebum that contributes to acne pathogenesis. Clascoterone application to acne-prone skin delivers AR antagonist activity directly to the sebocyte population, blocking DHT signaling and reducing sebum production locally. Clinical trials have documented reduction in measured skin surface sebum in clascoterone-treated patients — a direct biomarker of mechanism — alongside the clinical improvement in acne lesion counts. This sebum-reduction mechanism is what distinguishes clascoterone from purely anti-comedogenic (retinoid) or antimicrobial (benzoyl peroxide, antibiotic) topical agents — it addresses the androgen-driven pillar of acne pathogenesis that topical agents previously could not.
3. Dermal papilla AR blockade and hair follicle effects — the basis for alopecia investigation. The dermal papilla cells at the base of hair follicles contain androgen receptors; in genetically susceptible individuals, DHT binding to follicular AR drives hair follicle miniaturization, shortened anagen phase, and progression of androgenetic alopecia. Clascoterone applied to affected scalp (in the alopecia formulation) delivers AR blockade directly to follicular target tissues. In the Mazzetti 2019 pilot studyand subsequent Breezula Phase 2 data, clascoterone solution (typically 7.5% concentration for alopecia, higher than the 1% acne cream) has shown hair count increases over 6 months, consistent with the proposed mechanism of reversing DHT-mediated follicle miniaturization. The mechanism is pharmacologically rational; the clinical translation is still being established through ongoing Phase 2/3 development.
4. Rapid systemic hydrolysis to cortexolone — the key safety mechanism. Clascoterone's design incorporates the propionate ester specifically to enable rapid systemic hydrolysis once the compound enters plasma. Human plasma contains abundant esterases (carboxylesterase, cholinesterase, paraoxonase) that cleave ester bonds; for clascoterone, the 17α-propionate linkage is highly susceptible to rapid enzymatic hydrolysis, with a plasma half-life on the order of minutes. The hydrolysis product is cortexolone (11-deoxycortisol) — an endogenous steroid hormone intermediate that (a) has weak, non-selective AR binding affinity (orders of magnitude less than clascoterone or DHT); (b) has no significant glucocorticoid or mineralocorticoid agonist activity at physiological concentrations; (c) is further metabolized and cleared through normal steroid catabolic pathways. The net systemic exposure to active AR antagonist is therefore minimal after topical administration, even with large-surface-area application.
5. Local metabolism within skin — the therapeutic window. Skin tissue itself contains esterase activity that can hydrolyze clascoterone, but the local tissue concentration achieved immediately after topical application is substantially higher than systemic concentration, giving clascoterone sufficient time at target receptors to produce AR antagonism before local metabolism clears it. The therapeutic window depends on (a) cutaneous penetration and retention; (b) local versus systemic esterase activity; (c) binding to skin AR. The pharmaceutical formulation (1% cream for acne, higher-concentration solutions for alopecia) is optimized to achieve this window.
6. Lack of significant glucocorticoid agonist activity at therapeutic doses — a relevant distinction (Celasco 2004 early preclinical pharmacology). Cortexolone (the parent steroid scaffold) is structurally similar to cortisol but lacks the 11β-hydroxyl group that is essential for potent glucocorticoid receptor (GR) agonism. Cortexolone has been used historically as an 11-deoxy intermediate in steroid biosynthesis studies but does not produce the skin atrophy, telangiectasias, or other adverse effects characteristic of topical corticosteroids. Clascoterone similarly does not produce significant GR-mediated effects at therapeutic doses — it is not a corticosteroid, does not cause steroid-induced acne, does not produce skin atrophy, and should not be confused with topical corticosteroids. This distinction is important: clascoterone is a novel non-steroidal-in-activity compound despite its steroidal chemical scaffold.
7. HPA axis considerations — the pediatric open-label study finding. A 29-patient open-label maximum use pharmacokinetic/HPA axis safety study in pediatric patients (ages 9-11) with facial acne demonstrated HPA axis suppression in a subset of subjects at 2 weeks, defined by post-ACTH-stimulation cortisol below normal thresholds. Suppression was reversible on discontinuation and was not observed in older patients or in adults. The mechanism is thought to involve systemic absorption of cortexolone (the hydrolysis product) producing weak but measurable effects on HPA axis function at sufficient systemic exposure. The FDA labeling reflects this finding, cautioning monitoring in pediatric patients and with large-surface-area or occluded application. This is a real, though modest, mechanistic consideration — not a contraindication but a monitoring point, particularly relevant for clinicians considering off-label use in younger children or extensive body acne.
8. Comparison with systemic AR antagonists — mechanistic differentiation. Systemic AR antagonists used in clinical practice include: (a) spironolactone — a mineralocorticoid receptor antagonist with secondary AR antagonist activity, used in acne/alopecia primarily in women; carries hyperkalemia and menstrual irregularity risks; (b) finasteride — type 2 5α-reductase inhibitor (reduces DHT production rather than blocking AR); oral, systemic, with sexual function side effects; (c) dutasteride — dual 5α-reductase inhibitor; oral, more potent systemic DHT reduction; (d) ru-58841 — an investigational topical AR antagonist not FDA-approved, research/gray-market use only. Clascoterone differs from all of these in combining (i) topical delivery for local effect, (ii) competitive AR antagonism (not 5α-reductase inhibition), (iii) rapid systemic inactivation to minimize exposure, (iv) FDA approval with rigorous Phase 3 evidence — the package of topical potency, systemic safety, and regulatory validation is unique among AR-pathway-modulating compounds as of 2026.
9. Receptor specificity and off-target pharmacology. Clascoterone is designed for selective AR antagonism; its affinity for other steroid receptors (glucocorticoid, mineralocorticoid, estrogen, progesterone) is substantially lower at therapeutic concentrations. However, cortexolone (the hydrolysis product) has been described as a glucocorticoid receptor antagonist (weak partial agonist/antagonist) at certain concentrations; at systemic concentrations achieved after topical clascoterone application, GR effects are thought to be minimal. The HPA axis suppression observed in the pediatric study may reflect modest GR-pathway effects, competing cortisol-pathway metabolism, or feedback effects — the precise mechanism is not fully characterized but warrants the observed monitoring caution.
10. Pharmacokinetics after topical application — the key design feature. Published PK data from clinical trials indicate: (a) after twice-daily topical application of 1% clascoterone cream, systemic exposure is low — plasma clascoterone concentrations are typically below quantification limits or in the low picogram/mL range; (b) the small amount of systemic clascoterone that is detected is rapidly hydrolyzed to cortexolone with a systemic half-life of a few hours; (c) steady-state exposure is achieved within approximately 7 days of consistent twice-daily use; (d) maximum-use pharmacokinetic studies (large-surface-area, maximum-dose application) demonstrate that systemic exposure remains low even at application conditions well beyond typical clinical use; (e) the pediatric HPA axis safety study documented the only appreciable systemic exposure signal, concentrated in younger children with intensive use. This PK profile is the pharmacokinetic embodiment of the "topical potency, minimal systemic exposure" design philosophy.
11. Onset of clinical effect — mechanism-consistent timing (Draelos 2023 practical use review). Clinical acne improvement is typically observed over 4-12 weeks of consistent twice-daily application. This timeline reflects (a) the time required to shift sebum production kinetics through AR blockade of sebocytes; (b) the time for existing comedones and inflammatory lesions to resolve under reduced sebum pressure; (c) the turnover time of sebaceous gland cell populations. Rapid effects (days) are not expected; patients and clinicians should anticipate gradual improvement rather than dramatic early response. The alopecia response is even slower — hair cycle biology dictates that meaningful hair count improvements require 3-6 months minimum, with full effects at 6-12 months.
12. Mechanism vs clinical evidence — summary. Clascoterone's mechanism of action — topical AR antagonism with rapid systemic inactivation — is mechanistically plausible, pharmacologically rational, and now clinically validated for acne vulgaris through the Hebert 2020 Phase 3 RCTs. For hair loss, the mechanism is extrapolated and provisionally supported by the Mazzetti 2020 pilot study but awaits fuller Phase 3 validation. The pharmacology is well-characterized compared to most herbal or supplement compounds — this is a genuinely novel pharmaceutical with a well-understood molecular mechanism, not a poorly-characterized mixture. The mechanistic story supports both the therapeutic positioning (topical antiandrogen for androgen-influenced cutaneous conditions) and the safety positioning (minimal systemic exposure reduces the systemic-side-effect concerns of oral antiandrogens).
Overview
Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. Food and Drug Administration in August 2020 for the treatment of acne vulgaris in patients 12 years of age and older. It is chemically cortexolone 17α-propionate, an ester prodrug of cortexolone (11-deoxycortisol), designed to bind and competitively inhibit androgen receptors in cutaneous target tissues — specifically the sebocytes of sebaceous glands and dermal papilla cells of hair follicles — and then to be rapidly hydrolyzed to cortexolone in plasma so that systemic androgen blockade is minimized. This pharmacologic strategy — potent local AR antagonism with rapid systemic deactivation — makes clascoterone meaningfully different from oral antiandrogens like spironolactone and finasteride, which produce systemic androgen-pathway effects and carry the corresponding systemic side effect profile (menstrual irregularity, gynecomastia, sexual dysfunction, potassium/electrolyte concerns). Clascoterone was developed by Cassiopea S.p.A. (an Italian dermatology-focused pharmaceutical company spun out of Cosmo Pharmaceuticals) over roughly two decades of preclinical and clinical development, culminating in two identically-designed Phase 3 randomized placebo-controlled trials (NCT02608775 and NCT02608827) published in JAMA Dermatology in 2020 by Hebert and colleagues (PMID: 32320027), demonstrating statistically significant improvements in acne lesion counts and Investigator's Global Assessment (IGA) success rates over 12 weeks.
Important framing up front: Clascoterone is a genuine, novel, FDA-approved pharmaceutical with two well-designed Phase 3 randomized controlled trials supporting its efficacy in acne vulgaris — not an herbal supplement, not a cosmeceutical, not an extrapolated off-label use. The evidence base for the labeled indication (acne vulgaris, age 12+, twice-daily topical application of 1% cream) is solid by dermatology standards: thousands of patients randomized in the key trials, placebo-controlled design, consistent efficacy signal across both studies, and acceptable safety profile at the topical dose. It represents the first entirely new mechanism-of-action topical acne treatment in nearly 40 years — the prior generation of topical acne therapeutics (retinoids, benzoyl peroxide, topical antibiotics) addresses the inflammatory and microbial pillars of acne pathogenesis, while clascoterone is the first topical agent to directly target the androgen-driven sebogenesis pillar that had previously required systemic therapy (oral antiandrogens, hormonal contraceptives, isotretinoin) to address. This is a genuinely new therapeutic option for the subset of acne patients whose disease is substantially androgen-driven and who either cannot tolerate, do not want, or have contraindications to systemic antiandrogen therapy.
Honest positioning — what clascoterone is and is not: Clascoterone is (1) the first topical AR antagonist approved for acne in adolescents and adults 12+; (2) efficacious but modestly so — in the Phase 3 trials, IGA treatment success was achieved in roughly 18-20% of clascoterone-treated patients vs 7-9% of vehicle-treated patients at 12 weeks, a real and statistically significant but not dramatic effect magnitude; (3) well-tolerated with the most common side effects being mild application site reactions (erythema, scaling, dryness, pruritus) at rates comparable to the vehicle cream; (4) potentially useful off-label for androgenetic alopecia (male pattern hair loss) based on a single published pilot study (Mazzetti 2019) and an active Phase 2/3 development program by Cassiopea under the Breezula brand, though this off-label use is not FDA-approved and rests on preliminary evidence. Clascoterone is not (1) a replacement for isotretinoin in severe nodulocystic acne — isotretinoin remains the definitive treatment for severe disease; (2) as potent as systemic antiandrogens for severe hormonal acne — spironolactone typically produces more dramatic improvements in severe hormonal acne in women; (3) a proven hair loss treatment — the alopecia evidence is preliminary, and minoxidil plus finasteride (or dutasteride) remain the evidence-based gold standard; (4) without risk — the FDA label includes a caution about hypothalamic-pituitary-adrenal (HPA) axis suppression observed in a pediatric open-label safety study, warranting careful monitoring particularly in children and with large-surface-area application. Men and women considering clascoterone should understand it as a real but targeted therapeutic option — useful within its proven indication (topical acne therapy 12+) and potentially useful in the investigational hair loss space, not as a miracle cure or as a categorically superior alternative to established acne or alopecia therapies.
Regulatory and development history: The clascoterone program originated in the early 2000s with preclinical work at Cosmo Pharmaceuticals on cortexolone-based compounds as topical androgen modulators. Cortexolone itself — 11-deoxycortisol, an intermediate in cortisol biosynthesis — has weak but real affinity for both the glucocorticoid receptor and the androgen receptor, with some selectivity for the AR at certain tissue levels. The propionate ester (cortexolone 17α-propionate, later named clascoterone) was developed to improve lipid-solubility and skin-penetration properties, giving the compound enhanced topical bioavailability at the target cutaneous tissues while retaining rapid systemic hydrolysis to cortexolone upon absorption into plasma. This design philosophy — topical efficacy with minimal systemic exposure — is fundamental to the clascoterone safety positioning and distinguishes it from orally-administered AR antagonists. Cassiopea (formed as a dermatology-focused spin-off from Cosmo) took clascoterone through Phase 2 and Phase 3 development between approximately 2010 and 2019, with the acne Phase 3 trials (CB-03-01/25 and CB-03-01/26, corresponding to NCT02608775 and NCT02608827) completing enrollment in 2018-2019 and reporting in 2020. FDA approval was granted in August 2020 for the 1% cream formulation under the brand name Winlevi, with indication for "the topical treatment of acne vulgaris in patients 12 years of age and older." Marketing in the US commenced in 2021 through Sun Pharmaceutical, which acquired North American commercialization rights from Cassiopea. The alopecia development program (Breezula) has proceeded on a separate timeline, with Phase 2 data published from Mazzetti and colleagues and Phase 3 development ongoing as of this writing.
Claimed benefits and where evidence supports them: The rigorously evidenced benefit is acne vulgaris symptom improvement — specifically, reduction in non-inflammatory (comedonal) and inflammatory (papular, pustular) acne lesion counts, and achievement of "Investigator's Global Assessment success" (defined as IGA score of 0 or 1 — clear or almost clear — with at least a 2-point improvement from baseline) over 12 weeks of twice-daily topical application. The Hebert 2020 JAMA Dermatology publication (PMID: 32320027) reports: (1) IGA treatment success at week 12: ~18-20% on clascoterone vs ~7-9% on vehicle across both studies (absolute difference ~10-11%, statistically significant); (2) mean absolute reduction in inflammatory lesions: ~45% on clascoterone vs ~33% on vehicle; (3) mean absolute reduction in non-inflammatory lesions: ~42% on clascoterone vs ~30% on vehicle; (4) consistent efficacy across adolescent (12-17) and adult (18+) subgroups. These are clinically meaningful but not dramatic effects — patients treated with clascoterone can expect modest-to-moderate improvement, particularly in patients whose acne has a significant androgen-driven component (oilier skin, cyclical menstrual flares in women, response to oral antiandrogens in prior treatment). Less rigorously evidenced benefits include: (a) improvement in androgenetic alopecia — Mazzetti 2020 pilot study in men with male pattern hair loss showed hair count improvements over 6 months at higher clascoterone solution concentrations, but the trial was small (n=36) and open-label; larger Phase 2/3 Breezula trials are ongoing; (b) potential utility in hidradenitis suppurativa, folliculitis, seborrheic dermatitis, and other androgen-influenced cutaneous conditions — mechanistically plausible but not formally studied in RCTs; (c) cosmetic benefit in oily-skin/sebum-overproduction contexts — extrapolated from sebocyte AR blockade, not directly studied as a cosmetic endpoint.
Where evidence does NOT support clascoterone: (1) not a proven hair loss treatment — the alopecia evidence is preliminary; the compound is not FDA-approved for hair loss; (2) not established in pediatric populations under 12 — safety data specifically in younger children is limited and HPA axis suppression has been observed in pediatric open-label safety studies; (3) not a replacement for systemic acne therapy in severe disease — severe nodulocystic acne, scarring acne, and acne unresponsive to topical/systemic standard therapies warrant isotretinoin or other systemic options; (4) not studied in pregnancy or lactation — Pregnancy Category has been designated with insufficient data; avoid during pregnancy/breastfeeding until more data available; (5) not demonstrated to be superior to established topical therapies — comparative trials against tretinoin, adapalene, benzoyl-peroxide, or topical antibiotics are limited; most clinical use positions clascoterone as adjunctive or complementary to (not replacing) established topical acne regimens.
Novel mechanism and why it matters: Acne vulgaris pathogenesis involves four interacting pillars — (1) androgen-driven sebogenesis (excess sebum production by sebocytes); (2) follicular hyperkeratinization and comedogenesis; (3) Cutibacterium acnes (formerly Propionibacterium acnes) colonization and biofilm formation; (4) inflammation. Traditional topical acne therapies address pillars 2-4: topical retinoids (tretinoin, adapalene, trifarotene) normalize keratinization and reduce inflammation; benzoyl peroxide kills C. acnes; topical antibiotics (clindamycin, erythromycin) suppress C. acnes; newer agents like topical azelaic acid, dapsone, and minocycline address multiple pillars. None of the prior topical agents directly target pillar 1 (androgen-driven sebogenesis). Systemic treatments do — oral contraceptives, spironolactone, finasteride, and isotretinoin all modulate sebum production through androgen-pathway or sebaceous-gland-specific mechanisms — but at the cost of systemic exposure and the corresponding side-effect profile. Clascoterone is the first topical agent to target pillar 1 directly, potentially complementing prior topical regimens by addressing a mechanism they could not. This is not a trivial advance — for patients whose acne is substantially androgen-driven (many adult women with persistent acne, adolescents with oilier/sebaceous-rich skin, patients with polycystic ovary syndrome or similar hyperandrogenic conditions), a topical AR antagonist represents a genuinely new therapeutic lever that was not previously available.
Off-label hair loss context — emerging but not established: Androgenetic alopecia (male pattern baldness, female pattern hair loss) involves progressive miniaturization of hair follicles in genetically susceptible individuals, driven largely by local conversion of testosterone to dihydrotestosterone (DHT) within the follicle via 5α-reductase and subsequent DHT-mediated activation of androgen receptors in dermal papilla cells. Current evidence-based therapies include: (1) minoxidil (topical 2%, 5%, or oral low-dose) — FDA-approved, works via unclear vasodilatory/follicle-stimulating mechanism, not anti-androgenic; (2) finasteride (1 mg oral) — FDA-approved for male pattern hair loss, inhibits type 2 5α-reductase systemically, reduces DHT by ~70%; (3) dutasteride (oral, off-label for hair loss) — dual 5α-reductase inhibitor, more potent DHT suppression; (4) topical finasteride or dutasteride (compounded or emerging prescription products; Piraccini 2022) — attempt to achieve local scalp effect with less systemic exposure. Clascoterone's proposed role in alopecia is as a topical AR antagonist — blocking DHT action at the follicle rather than blocking DHT production as 5-ARIs do. The Mazzetti 2020 pilot study showed hair count improvements at the 7.5% clascoterone solution concentration over 6 months in men with androgenetic alopecia. Caveats: (a) single small pilot study; (b) the alopecia formulation is different from the acne cream (higher concentration, solution vehicle); (c) not FDA-approved for hair loss; (d) available only through compounding pharmacies or research protocols outside of acne-indication use; (e) longer-term efficacy data, comparative data against minoxidil/finasteride, and optimal combination protocols remain to be established.
Clascoterone sits alongside spironolactone, finasteride, dutasteride, ru-58841, saw-palmetto, and pygeum within the broader category of compounds that modulate androgen pathways, but it is distinctive in being (a) topically administered, (b) FDA-approved for acne specifically, (c) rapidly systemically deactivated to minimize systemic exposure, and (d) mechanistically novel (first topical AR antagonist). This is educational content and not medical advice; anyone considering clascoterone for acne should involve a dermatologist, particularly given the specificity of indication and the HPA axis suppression considerations; anyone considering off-label use for hair loss should involve a dermatologist or hair-loss specialist and understand that the hair loss evidence is preliminary, the preparation typically requires compounding, and cost-benefit versus established therapies (minoxidil, finasteride) is not yet established.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
Known hypersensitivity to clascoterone or components of the cream/solution formulation (including vehicle excipients, preservatives, or propylene glycol in compounded preparations) — discontinue if rash, swelling, significant redness, or systemic allergic symptoms occur.
Pregnancy — clascoterone has not been adequately studied in human pregnancy. FDA labeling notes insufficient data to establish safety. Animal studies have not shown clear reproductive toxicity at clinically relevant doses, but human pregnancy data are minimal. Recommendation: avoid clascoterone during pregnancy. Women of childbearing age who become pregnant during clascoterone treatment should discontinue and inform their physician. For pregnant patients with acne, alternatives with better-established safety profiles include azelaic acid, topical erythromycin, and gentle cleansing; some experts consider topical benzoyl peroxide acceptable. Isotretinoin is absolutely contraindicated in pregnancy (teratogenic); oral tetracyclines are contraindicated after the first trimester.
Breastfeeding — whether clascoterone or its metabolites (cortexolone) are excreted in human milk is not well-characterized; systemic exposure from topical use is low but not zero. Recommendation: avoid clascoterone in breastfeeding when possible; if use is necessary, apply only to small areas away from breast tissue, do not apply immediately before nursing, and discuss with healthcare provider. Alternative acne therapies with better-established lactation safety profiles are typically preferred.
Pediatric use under 9 years — not studied; no safety or efficacy data; not recommended.
Relative contraindications requiring medical guidance:
Pediatric use 9-11 years — clascoterone is FDA-approved for 12+; off-label use in 9-11 is sometimes considered for severe early-onset acne but should involve (a) dermatologist involvement; (b) limited treatment surface area; (c) HPA axis monitoring consideration given the pediatric HPA axis study findings; (d) weighing benefits of treatment vs risks of non-treatment (psychosocial impact of severe acne in this age group).
Extensive body acne requiring large-surface-area application — the HPA axis suppression concern becomes more relevant with large-surface-area topical application; for patients requiring treatment of face plus shoulders, chest, or back, consider: (a) starting with limited surface area and assessing; (b) avoiding occlusive application; (c) HPA axis monitoring at baseline and periodically; (d) weighing risk-benefit vs alternative therapies (oral antibiotics, isotretinoin).
Concurrent systemic or topical corticosteroid use — combining clascoterone (which may produce mild systemic effects on cortisol pathway) with other corticosteroid therapies increases theoretical HPA axis suppression concern. If concurrent corticosteroid use is necessary, monitor accordingly and consider specialty consultation.
Broken, abraded, or significantly inflamed skin — avoid application directly to broken skin; percutaneous absorption is increased and irritation potential higher. Allow skin to heal before resuming application.
Concurrent isotretinoin therapy — typically not combined; isotretinoin provides dominant acne effect; clascoterone is redundant and may additively increase dryness/irritation. Sequential use (clascoterone before or after isotretinoin course) is reasonable; simultaneous use during isotretinoin is generally avoided.
Active cancer treatment — discuss with oncology team. Clascoterone itself is not a chemotherapy or oncologic agent; most oncology teams do not specifically prohibit acne therapy but want awareness of all concurrent medications. For prostate cancer patients receiving systemic antiandrogen therapy (e.g., bicalutamide, enzalutamide, abiraterone), topical clascoterone would be redundant and unnecessary; for other cancer patients with acne (including acneiform eruptions from EGFR inhibitors), consultation with oncology-dermatology is appropriate.
History of adrenal insufficiency or HPA axis disorders — use with caution given the HPA axis suppression signal in pediatric studies; consider alternative therapies or monitor HPA axis function during treatment.
History of severe allergic reactions to topical skincare products or cosmetics — introduce clascoterone cautiously with small test area initially; stop if reaction develops.
Eye area, lips, mucous membranes — do not apply to eyes, mouth, inside nostrils, lips, or mucous membranes; clascoterone is for skin application only. Accidental contact requires rinsing with water.
Situations warranting medical consultation before use:
- Pregnancy, actively planning pregnancy, or pregnancy possibility
- Breastfeeding
- Pediatric age under 12 (off-label consideration)
- Extensive body acne requiring large-surface treatment
- Known HPA axis or adrenal insufficiency history
- Active oncologic treatment
- Severe acne potentially requiring isotretinoin instead
- Uncertainty about diagnosis (acne vs rosacea vs folliculitis vs perioral dermatitis)
Pregnancy testing considerations: For women of childbearing potential prescribed clascoterone for facial acne without concurrent contraception concerns, routine pregnancy testing is not mandated (unlike isotretinoin under iPLEDGE program). However, women should be counseled about pregnancy avoidance during treatment; any missed period or pregnancy concern warrants pregnancy test and discontinuation.
Signs and symptoms suggesting need for discontinuation:
- Severe or persistent application site reactions not responding to typical management (dose reduction, moisturization)
- Signs of allergic reaction: significant rash beyond application site, angioedema, respiratory symptoms (extraordinarily rare but possible)
- Symptoms suggesting adrenal insufficiency: persistent fatigue, unexplained weakness, weight loss, orthostatic symptoms, electrolyte abnormalities — evaluate and discontinue if suspicion is substantial
- Pregnancy confirmation during treatment
- Inadequate response after 12-16 weeks consistent use — consider alternative or combination therapy
- Worsening acne despite treatment — reassess diagnosis, adherence, potential underlying contributions
Drug interaction considerations for contraindication evaluation:
- Most prescription medications: compatible with topical clascoterone given low systemic exposure.
- Other topical antiandrogens (e.g., topical flutamide, topical spironolactone in compounded preparations) — theoretical redundancy; not typically combined.
- Oral/systemic corticosteroids: theoretical combined HPA axis concern, particularly with prolonged systemic steroid therapy + extensive surface area clascoterone use.
- Topical corticosteroids: avoid simultaneous application to the same region; use at different times if both needed; consider HPA axis monitoring with prolonged combined use.
Legal and regulatory status: Clascoterone (Winlevi brand) is an FDA-approved prescription topical dermatologic agent in the United States, indicated for acne vulgaris in patients 12 years and older. Marketing authorization has been obtained in the European Union, United Kingdom, and various other markets. Not a controlled substance; not scheduled; requires prescription for access. International availability and brand names vary by market; Winlevi is the primary brand in US and North America, marketed by Sun Pharmaceutical under license from Cassiopea. Compounded preparations for off-label use (particularly alopecia) require prescription and are prepared by accredited compounding pharmacies. WADA permits clascoterone for topical use (not a performance-improving substance; not on prohibited list).
Post-marketing surveillance: The FDA MedWatch program accepts adverse event reports; patients or clinicians noting unexpected or serious adverse events can report to FDA (1-800-FDA-1088 or online). Post-marketing safety monitoring has not identified new safety concerns beyond the HPA axis suppression finding from the pediatric study and the expected application site reactions.
Quality variability — primarily a compounded-preparation concern: Commercial Winlevi is pharmaceutical-grade and highly consistent. Compounded clascoterone preparations can vary in quality depending on compounding pharmacy practices; choose accredited compounding pharmacies with good quality-control records.
Not medical advice: This content is educational. Clascoterone use should be under the guidance of a prescribing clinician (dermatologist, primary care, or appropriate specialist). Specific decisions — whether to use clascoterone for acne or off-label hair loss, combination regimen selection, HPA axis monitoring strategy, pregnancy planning — warrant physician involvement tailored to individual circumstances. Clascoterone is a real pharmaceutical with a real evidence base, but it is not a panacea and is not a substitute for complete dermatologic or hair-loss management.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Clascoterone.
Research Score
1188 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is clascoterone and how does it differ from spironolactone or finasteride?
Clascoterone (Winlevi) is the first FDA-approved topical androgen receptor antagonist for acne vulgaris, approved in August 2020 for patients 12 and older (Hebert 2020, PMID: 32320027; Rosette 2019, PMID: 31524341). It differs fundamentally from spironolactone and finasteride in being topical and locally-acting with minimal systemic exposure — by design. The mechanism: clascoterone is chemically cortexolone 17α-propionate, an ester prodrug of cortexolone. Applied topically at 1% cream concentration twice daily, it penetrates to target cutaneous tissues (sebocytes in sebaceous glands, dermal papilla cells in hair follicles) where it competitively inhibits androgen receptors, blocking dihydrotestosterone (DHT) action locally. When it absorbs into systemic circulation, plasma esterases rapidly hydrolyze it to cortexolone — an inactive metabolite with weak, non-selective AR binding — so systemic antiandrogen exposure is minimal. Key differences from spironolactone: (a) topical vs oral — clascoterone is applied to skin; spironolactone is taken by mouth and acts systemically; (b) local vs systemic — clascoterone's effects are concentrated at the site of application; spironolactone affects the entire body; (c) side effect profile — clascoterone's main side effects are mild application site reactions (redness, dryness) and potential HPA axis suppression with extensive use; spironolactone can cause hyperkalemia, menstrual irregularity, breast tenderness, and feminization in men; (d) sex-specific use — spironolactone is effectively limited to women (due to gynecomastia risk in men); clascoterone is appropriate for both sexes; (e) evidence base — clascoterone has FDA approval based on two Phase 3 RCTs for acne; spironolactone is used off-label for hormonal acne with substantial clinical experience but not formal acne indication. Key differences from finasteride: (a) clascoterone blocks the androgen RECEPTOR; finasteride inhibits 5α-reductase (enzyme that converts testosterone to DHT) — different mechanism; (b) clascoterone is topical; oral finasteride is systemic; (c) finasteride has FDA approval for male pattern hair loss (1 mg) and BPH (5 mg); clascoterone is FDA-approved only for acne; (d) finasteride's sexual dysfunction and post-finasteride syndrome concerns don't apply to topical clascoterone. When each is used: clascoterone is ideal for topical acne treatment in patients 12+ (approved indication) and is emerging for off-label androgenetic alopecia (hair loss); spironolactone is used for hormonal acne, PCOS-associated acne, and androgenetic alopecia in women (oral, systemic); finasteride is used for male pattern hair loss and BPH (oral, systemic). All three can be used individually or in combination depending on the clinical context and patient characteristics.
How well does clascoterone actually work for acne based on the clinical trials?
Clascoterone produces modest but statistically significant improvement in acne vulgaris — meaningful for many patients but not dramatic, and distinctly less potent than systemic therapies like isotretinoin (Hebert 2020, PMID: 32320027; Eichenfield 2020, PMID: 33006827). The pivotal evidence comes from two Phase 3 randomized placebo-controlled trials (Hebert et al. 2020, JAMA Dermatology, PMID: 32320027, based on NCT02608775 and NCT02608827; also see Rosette 2019, PMID: 31524341 for pharmacology background, and Kircik 2021, PMID: 33533555 for clinical commentary) that enrolled a combined 1,435 patients aged 9 and older with moderate-to-severe facial acne vulgaris, randomized to clascoterone 1% cream or vehicle twice daily for 12 weeks. Key efficacy results: (1) Investigator's Global Assessment (IGA) treatment success (defined as IGA score of 0 or 1 — clear or almost clear — with at least 2-point improvement): approximately 18-20% of clascoterone-treated patients vs 7-9% of vehicle-treated patients achieved success at week 12 — an absolute difference of ~10-11 percentage points, statistically highly significant. (2) Inflammatory lesion count reduction: clascoterone produced approximately 45% mean reduction from baseline vs 33% with vehicle. (3) Non-inflammatory (comedonal) lesion reduction: clascoterone ~42% vs vehicle ~30%. (4) Consistent efficacy across male and female patients, adolescent and adult subgroups, and moderate vs severe baseline severity. Clinical interpretation: this is a clinically meaningful but not dramatic effect. Roughly 1 in 5 clascoterone-treated patients achieve IGA success (clear or almost clear skin) at 12 weeks; many more experience partial improvement. Compare to: topical retinoids (IGA success ~15-25%); benzoyl peroxide (~15-25%); topical antibiotics in combination with BP (~20-30%); oral isotretinoin (~80-90% for severe acne); oral spironolactone in women with hormonal acne (~50-70% meaningful improvement). Clascoterone sits in the standard topical acne agent efficacy range — comparable to tretinoin and BP, not as potent as systemic therapies for severe acne. Time course: improvement is gradual; measurable effects begin around week 4-6; peak efficacy at week 12-16; steady maintenance thereafter with continued use. Patients most likely to respond: those with (a) significant androgen-driven acne component (oilier skin, adult women with hormonal patterns, PCOS-associated acne); (b) inflammatory and non-inflammatory lesions; (c) willingness to commit to consistent twice-daily application; (d) appropriate diagnostic confirmation (not rosacea, folliculitis, or other mimickers). Patients less likely to benefit: those with severe nodulocystic acne warranting isotretinoin; those seeking rapid dramatic clearance; those unable to maintain consistent twice-daily application; those whose acne is driven predominantly by non-androgen factors.
Can clascoterone help with male pattern baldness or female pattern hair loss?
Preliminary evidence suggests yes for both sexes, but this is off-label use that is not FDA-approved and rests on limited Phase 2 data rather than the strong Phase 3 evidence supporting the acne indication (Mazzetti 2019 AGA pilot, PMID: 31859456; Trüeb 2021 review, PMID: 34318977; broader topical antiandrogen context: Piraccini 2022, PMID: 34846066). The scientific rationale is strong: androgenetic alopecia (male pattern and female pattern hair loss) involves progressive hair follicle miniaturization driven largely by dihydrotestosterone (DHT) binding to androgen receptors in dermal papilla cells. Clascoterone's mechanism — topical competitive AR antagonism with rapid systemic hydrolysis — is mechanistically ideal for blocking DHT action at the follicle while avoiding systemic antiandrogen exposure. Key evidence — Mazzetti 2019 pilot study (PMID: 31859456): Mazzetti and colleagues published a Phase 2a dose-finding study randomizing 36 men aged 18-55 with Hamilton-Norwood grade III-V male pattern hair loss to placebo solution or clascoterone 2.5%, 5%, 7.5%, or 10% solutions, applied twice daily for 6 months. See also Trüeb 2021 review (PMID: 34318977) for context on topical antiandrogens in AGA. Results: statistically significant improvement in target area hair count at the 7.5% clascoterone solution (~7% increase from baseline vs placebo); numerically greater responses at higher concentrations (7.5% and 10%) compared to lower concentrations; favorable safety profile. Limitations: small sample (n=36), single pilot study, 6-month duration only (AGA response timelines are typically 12+ months for full evaluation), no long-term durability data, no female patients. Ongoing development: Cassiopea is developing clascoterone specifically for alopecia under the Breezula brand through Phase 2/3 trials. Results are anticipated to clarify (a) optimal concentration, (b) efficacy magnitude relative to established therapies, (c) durability, (d) efficacy in women, (e) combination regimens. Current off-label use practice: clinicians prescribing clascoterone for AGA typically use compounded solutions at 5-7.5% concentration, applied twice daily to affected scalp areas. Commonly combined with minoxidil 5% twice daily (complementary mechanism — minoxidil stimulates follicles via separate vasodilatory/growth pathways). For maximum effect, combined with finasteride 1 mg oral daily in men (triple mechanism attack). Comparison with established hair loss therapies: minoxidil has decades of evidence and FDA approval; finasteride has strong evidence and FDA approval for male pattern hair loss; dutasteride has stronger evidence in head-to-head with finasteride for AGA. Clascoterone is emerging — evidence-supported but preliminary; not yet demonstrated superior to established therapies. Honest positioning: clascoterone is a reasonable addition to a hair loss regimen for men and women who (a) understand it's off-label and preliminary evidence-based; (b) want a topical antiandrogen option; (c) have tolerated or failed or want complement to established therapies; (d) can afford compounded preparations ($75-200/month typical). It is not yet a first-line hair loss treatment; minoxidil ± finasteride remain the evidence-based gold standards.
Is clascoterone safe during pregnancy or breastfeeding?
Clascoterone should generally be avoided during pregnancy and used cautiously (if at all) during breastfeeding. Insufficient human pregnancy and lactation data support this precautionary approach despite the relatively low systemic exposure with topical use (Chi 2016 antiandrogen pregnancy review, PMID: 27176111; Dhillon 2020, PMID: 33030712). Pregnancy: Clascoterone has not been adequately studied in human pregnancy. The FDA labeling reflects insufficient data to establish safety. Animal reproductive studies have not shown clear teratogenicity or major adverse fetal effects at clinically relevant doses, but the absence of robust human data warrants precaution. The theoretical concern: topical antiandrogens, if absorbed systemically during pregnancy, could theoretically affect androgen-dependent fetal development — particularly male fetal genital development, which is DHT-dependent (see general antiandrogen safety reviews: Chi 2016, PMID: 27176111). Clascoterone's design (rapid hydrolysis to inactive cortexolone) minimizes systemic exposure, but any systemic absorption during critical developmental windows (especially first trimester) is a theoretical concern. Recommendation: women who are pregnant or who become pregnant during clascoterone treatment should discontinue and inform their physician. For women of childbearing age on clascoterone, effective contraception is reasonable though not mandated (unlike isotretinoin, which requires the iPLEDGE program). Safer alternatives in pregnancy: for acne during pregnancy, topical agents with better-established safety records include azelaic acid (generally considered safe), erythromycin topical (relatively safer), and gentle non-pharmacologic management. Benzoyl peroxide is considered acceptable by many experts. Tretinoin is often avoided in pregnancy (some data suggest acceptable but many clinicians prefer caution). Isotretinoin is absolutely contraindicated (known teratogen). Oral tetracyclines are contraindicated after the first trimester. Breastfeeding: whether clascoterone or cortexolone are excreted in human milk is not well-characterized. Systemic exposure from topical use is low but not zero. Recommendation: avoid clascoterone during breastfeeding when possible; if use is necessary, apply only to small areas away from breast tissue, avoid application immediately before nursing, and discuss with both the patient's dermatologist and the pediatrician. Alternative acne therapies with better-established lactation safety are typically preferred. Planning for pregnancy: women considering pregnancy should typically discontinue clascoterone before conception if possible; after conception and delivery, can resume after breastfeeding ends. This is prudent given the preliminary pregnancy/lactation safety data and the availability of alternatives for the limited pregnancy/breastfeeding duration. The perspective for discussions with physician: pregnancy-related acne is often a self-limiting issue that improves postpartum as hormonal fluctuations stabilize. Aggressive acne therapy in pregnancy should generally be reserved for severe cases where benefits clearly outweigh theoretical risks, and clascoterone's limited pregnancy safety data typically positions it as not the preferred option during pregnancy/lactation.
What side effects should I expect on clascoterone, and what are the concerning ones?
Most patients tolerate clascoterone well — the most common side effects are mild application site reactions occurring in 2-4% of users, similar to vehicle placebo rates in clinical trials. The notable safety concern requiring monitoring is potential HPA axis suppression observed in pediatric maximum-use studies (Hebert 2020, PMID: 32320027; Mazzetti 2022 pediatric HPA study, PMID: 35575787; Dhillon 2020, PMID: 33030712). Expected common side effects (mild, generally self-limiting): (1) Application site erythema (redness) — 2-4%; usually transient and resolves with continued use; (2) Application site scaling or dryness — 1-3%; managed with moisturizer after absorption; (3) Application site pruritus (itching) — 1-2%; mild; (4) Application site stinging or burning on application — occasional, mild, transient; (5) Application site dermatitis — uncommon; persistent significant reaction warrants evaluation. Management: apply to clean dry skin; use fragrance-free non-comedogenic moisturizer after absorption; reduce to once-daily temporarily if irritation occurs; avoid concurrent harsh exfoliants or fragranced products; space application of other topical therapies (retinoids, BP) by 15-30 minutes. HPA axis suppression — the important monitoring point: A 29-patient pediatric open-label safety study (ages 9-11, moderate-to-severe facial acne, applying 1% cream twice daily to face and shoulders for 2 weeks under maximum-use conditions; Mazzetti 2022, PMID: 35575787) showed ~17% (5/29) of patients developed reversible HPA axis suppression defined by post-ACTH-stimulation cortisol below normal thresholds. Key context: (a) suppression was reversible on discontinuation within 4 weeks; (b) no subject developed clinical adrenal insufficiency during the study; (c) suppression was concentrated in the youngest age range with intensive application conditions; (d) has NOT been widely observed in older adolescents or adults under routine use. What this means clinically: (1) FDA labeling cautions about HPA axis suppression, particularly with pediatric use or large-surface-area application; (2) routine HPA axis testing is not mandatory for all patients but should be considered in (a) pediatric patients, especially under 12; (b) patients with extensive body acne requiring large treatment surface area; (c) prolonged continuous use cases; (3) watch for adrenal insufficiency signs: persistent fatigue, weakness, weight loss, orthostatic dizziness, hyperpigmentation, electrolyte abnormalities — any of these warrants discontinuation and medical evaluation. What clascoterone does NOT cause (or rarely causes): (1) systemic antiandrogen effects — no gynecomastia, sexual dysfunction, or menstrual irregularity at topical doses (contrasts with systemic spironolactone or finasteride); (2) skin atrophy — clascoterone is not a corticosteroid; (3) photosensitivity increase — standard sun protection, not specifically mandated; (4) hyperkalemia or electrolyte disturbance from typical use; (5) pregnancy teratogenicity signals in animal studies (though human data insufficient). When to stop and seek evaluation: (1) any signs of allergic reaction (severe rash, angioedema, wheezing — extraordinarily rare); (2) persistent severe application site reactions; (3) symptoms of adrenal insufficiency; (4) pregnancy confirmation; (5) inadequate response at 12-16 weeks (consider alternative or combination therapy).
How long does clascoterone take to work and how long should I stay on it?
Clascoterone's acne effects build gradually over 4-12 weeks of consistent twice-daily use; meaningful improvement is typical by week 8-12; long-term continued use for sustained control is reasonable as long as it remains effective and well-tolerated (Hebert 2020, PMID: 32320027; Eichenfield 2020 open-label extension, PMID: 33006827). Time course of effect: (1) First 1-2 weeks: no noticeable acne improvement expected; primary focus is tolerability assessment — does the skin tolerate twice-daily application without significant irritation? (2) Weeks 2-4: some patients begin to notice mild improvement — fewer new breakouts, slightly less oily skin feel; still in the 'is it working?' phase for most. (3) Weeks 4-8: progressive improvement for responders — reduction in inflammatory lesion count, fewer new comedones; patients often notice clearer skin by this point. (4) Weeks 8-12: peak efficacy achieved for most responders; the Phase 3 trials measured primary endpoints at week 12; by this point, if clascoterone is going to work for you, it has been clearly working; if there's no meaningful improvement, the response is likely inadequate. (5) Beyond 12 weeks: continued use maintains the improvement; many patients continue to see gradual additional progress for 16-24 weeks before reaching a stable improved baseline. Why the slow onset: clascoterone works by blocking androgen-driven sebum production in sebaceous glands; this pharmacologic effect takes time to translate into clinical improvement because (a) existing comedones take weeks to resolve under reduced sebum pressure; (b) inflammatory lesions need time to heal; (c) sebaceous gland function shifts over weeks rather than days; (d) hair follicle / skin turnover cycle is gradual. Compare to faster-acting therapies: oral antibiotics (anti-inflammatory effects in 1-2 weeks); benzoyl-peroxide (active C. acnes kill in days); isotretinoin (dramatic sebum reduction within weeks but longer full clearance); spironolactone (measurable improvement in 6-12 weeks for hormonal acne). Clascoterone is in the gradual-onset category. Assessment points: (1) Week 4 — tolerability check; (2) Week 8 — mid-course assessment of early response; (3) Week 12 — primary efficacy assessment; this is the point for deciding continue/escalate/alternate; (4) Week 16-24 — further refinement of response for continuers. Duration of continued use: Once clascoterone is providing clear benefit with good tolerability, continued use as part of ongoing acne management is reasonable. Many acne patients use topical therapies chronically because the underlying pathophysiology (androgen-driven sebogenesis, comedogenesis) persists; discontinuing often leads to flare recurrence. Reassess every 6-12 months: (a) is the current regimen still providing adequate control? (b) tolerability maintained? (c) any new considerations (pregnancy plans, cost, new therapies available)? (d) can regimen be simplified or stepped down in patients with sustained clear skin? Long-term safety: the clinical safety database includes up to 12 months of continuous use (open-label extension); no new adverse event signals beyond the pivotal 12-week trials. Use beyond 12-24 months is based on extrapolation and accumulated clinical experience; generally considered acceptable at routine doses. Step-down strategies: after 6-12 months of sustained good acne control, some patients can step down — e.g., maintenance with topical retinoid only, or clascoterone reduced to once-daily, or seasonal use if acne is worse in certain seasons. Individualize with prescriber.
Can I use clascoterone together with tretinoin, benzoyl peroxide, or other acne medications?
Yes — combination therapy is the typical clinical use pattern for clascoterone, and it combines well with most established topical and systemic acne treatments (AAD acne guidelines: Zaenglein 2016, PMID: 26897386; and combination regimen review: Del Rosso 2017, PMID: 29090056). Because clascoterone addresses a unique mechanism (topical androgen receptor antagonism / sebocyte modulation) that was not previously available in topical form, it layers well with established therapies that target other pillars of acne pathogenesis. Topical retinoid combinations (tretinoin, adapalene, trifarotene): the gold-standard combination. Clascoterone addresses sebogenesis; retinoid normalizes keratinization and reduces comedogenesis. Timing: apply clascoterone morning and evening to clean dry skin, let absorb ~15-30 min, then apply retinoid at bedtime (so evening has clascoterone first, then retinoid on top after absorption). Alternative: morning clascoterone, evening retinoid only (simpler but reduced clascoterone dose). Benzoyl peroxide combinations (benzoyl-peroxide): also common; clascoterone addresses sebogenesis; BP addresses C. acnes and has anti-inflammatory effects. Timing: typically BP wash or gel in morning, clascoterone morning and evening; or BP evening and clascoterone both times. Caveat: BP bleaches fabrics (sheets, pillowcases, white clothes); warn about fabric contact. Triple topical regimen — clascoterone + retinoid + BP: intensive topical approach for moderate acne; addresses androgens, comedogenesis, and C. acnes simultaneously. Example schedule: morning — cleanse, BP, clascoterone, moisturizer, sunscreen; evening — cleanse, clascoterone, wait, retinoid, moisturizer. Requires commitment and irritation management. Topical antibiotics (clindamycin, erythromycin): compatible; typically combined with BP to reduce resistance risk; clascoterone added as fourth component targets a different pillar. Oral antibiotics (doxycycline, minocycline): often used short-course (8-12 weeks) to rapidly reduce inflammation while topical regimen builds; clascoterone continues throughout. Systemic antiandrogens — spironolactone for women, oral contraceptive pills: compatible and often combined for hormonal acne in women; clascoterone provides local sebocyte AR blockade while spironolactone/OCP provides systemic hormonal modulation. Isotretinoin: typically NOT combined during active isotretinoin course because (a) isotretinoin provides dominant acne effect (reduces sebum 90%), (b) clascoterone is redundant at that point, (c) combined may increase dryness/irritation burden. Sequential use (isotretinoin for severe acne → clascoterone for maintenance after) is reasonable. What to avoid combining: (1) simultaneous large-surface-area topical corticosteroid — theoretical combined HPA axis concern; (2) multiple overlapping topical antiandrogens (e.g., clascoterone + topical flutamide) — redundant, no added benefit, cost concern; (3) concurrent therapies that compound irritation (multiple strong retinoids, harsh AHA/BHA exfoliants, mechanical scrubs) — space or alternate. Practical combination guidance: (1) start simple — clascoterone alone or clascoterone + one partner (retinoid or BP) for 2-4 weeks to establish tolerability; (2) add additional components gradually once baseline tolerance is established; (3) manage irritation proactively with moisturizer and gentler regimens; (4) coordinate with dermatologist rather than self-assembling complex regimens; (5) give combinations adequate time — 12-16 weeks before declaring adequate or inadequate.
How much does clascoterone cost and is it covered by insurance?
Winlevi (brand-name clascoterone 1% cream) costs $500-700 per 60-gram tube at US retail without insurance, but manufacturer savings programs and insurance coverage often reduce out-of-pocket cost substantially — typically to $25-75/month with insurance plus copay savings card. Off-label compounded clascoterone for hair loss is typically $75-200/month (see cost-benefit commentary: Dhillon 2020 clascoterone drug review, PMID: 33030712). US retail pricing breakdown: (1) Winlevi 60g tube list price: approximately $550-650 at major pharmacies (CVS, Walgreens, Rite Aid) as of 2026; (2) With commercial insurance: variable based on plan formulary; some plans cover Winlevi with tier-3 brand copay ($60-150/month typical); others require prior authorization or step therapy through generic alternatives; (3) Manufacturer copay savings card: Sun Pharmaceutical offers a copay card for eligible commercially-insured patients that can reduce copay to as low as $25/month; check manufacturer website for current program terms; (4) Without insurance and without savings: full retail $500-700/month is the typical out-of-pocket; (5) With goodRx or discount pharmacy programs: typically $400-600 — less savings than for generics but often modest reduction; (6) Medicare Part D: variable; Winlevi is typically tier 3 or 4, with substantial out-of-pocket on many plans; some patients hit Part D 'donut hole' on chronic use; (7) Medicaid: varies by state formulary; Winlevi is generally covered but may require prior authorization. Insurance coverage strategies: (1) Prior authorization — often required; dermatologist documents diagnosis, prior therapy failures, medical necessity; typical PA success rate is moderate-to-high for moderate-severe acne; (2) Step therapy — some plans require documented failure of generic alternatives (topical retinoids, BP, topical antibiotics) before covering Winlevi; dermatologist can document this history; (3) Formulary appeals — if initial coverage denied, appeals sometimes successful with additional documentation; (4) Specialty pharmacy — some plans require dispensing through specialty pharmacies; (5) Patient assistance programs — Sun Pharmaceutical offers need-based patient assistance for uninsured or underinsured patients; qualification is income-based; application process involves paperwork but can provide low-cost or free medication for eligible patients. Off-label compounded clascoterone for hair loss pricing: (1) Compounded solutions (typical 5-7.5% concentration): $75-150/month for single-active solution; (2) Combined preparations (clascoterone + minoxidil, clascoterone + topical finasteride): $100-250/month; (3) Specialty hair-loss pharmacies (Strut Health, Happy Head, Hims/Hers partner pharmacies): subscription model, typically $50-150/month depending on formulation; (4) Generic substitutions: clascoterone is not yet available as generic in US; commercial Winlevi or compounded preparations are the options. International pricing: (1) European markets (UK, EU, etc.): Winlevi is available; pricing varies by country; national health systems (NHS, national insurance) may or may not cover; private prescription prices can be more or less favorable than US; (2) Canadian pricing: typically more favorable than US retail for branded pharmaceuticals; (3) Developing markets: availability and pricing vary; some markets have Winlevi access, others do not. Generic timing: as of 2026, no generic clascoterone is available in US. Clascoterone's patent landscape and first-in-class status mean generic entry is not anticipated before approximately 2030-2032 based on standard pharmaceutical patent timelines. Cost-benefit perspective: compared to oral antibiotic courses, isotretinoin (typically $300-500/month plus monitoring labs), or specialty dermatologist visits without insurance, clascoterone at $25-75/month with insurance+savings is reasonable for committed acne therapy. Without insurance, $500-700/month retail is substantial; patient assistance programs or alternative therapies (generic topicals, oral antibiotics, spironolactone in women) may be more cost-effective.
How does clascoterone compare to other topical acne treatments like retinoids or benzoyl peroxide?
Clascoterone is a meaningful addition to the topical acne toolkit but does not categorically replace retinoids or benzoyl peroxide — it targets a different mechanism (androgen-driven sebogenesis) and is most effective in combination with these established agents rather than as a monotherapy replacement (Reynolds 2024, PMID: 38519146; Eichenfield 2020, PMID: 33006827). Mechanism comparison (see Zaenglein 2016 AAD acne guidelines, PMID: 26897386, and Reynolds 2024 ACMG/NICE update review, PMID: 38519146): (1) Topical retinoids (tretinoin, adapalene, trifarotene): normalize follicular keratinization, reduce comedogenesis, have anti-inflammatory effects; address the 'comedogenesis' pillar of acne pathogenesis; (2) Benzoyl-peroxide: antimicrobial against Cutibacterium acnes, mild comedolytic, anti-inflammatory; addresses the 'microbial' pillar; (3) Topical antibiotics (clindamycin, erythromycin): anti-C. acnes, anti-inflammatory; microbial pillar; (4) Topical dapsone, topical minocycline: anti-inflammatory, mild antimicrobial; inflammatory/microbial pillars; (5) Clascoterone: competitive androgen receptor antagonism in sebocytes; addresses the 'sebogenesis/androgen' pillar that prior topical agents did not address. Efficacy comparison: as monotherapy over 12 weeks in moderate acne, clascoterone produces approximately 18-20% IGA success rate — comparable to topical retinoids as monotherapy (15-25%) and BP as monotherapy (15-25%). Combination therapy (retinoid + BP, or retinoid + BP + clascoterone) produces higher success rates than any single agent; clinical guidelines generally recommend combination approaches for moderate acne. Tolerability comparison: (1) Clascoterone — well-tolerated; mild application site reactions in 2-4%; no photosensitivity increase; no skin atrophy; no fabric bleaching; (2) Topical retinoids — moderately tolerated initially; retinization irritation (erythema, peeling, dryness, photosensitivity) particularly in first 4-8 weeks; improved tolerance with time; require sun protection; (3) Benzoyl peroxide — generally tolerable; can cause dryness, erythema, peeling; bleaches fabrics; some patients develop irritant or contact dermatitis; (4) Topical antibiotics — generally very well-tolerated; minimal irritation. Where clascoterone shines: (1) Patients with hormonal acne features (adult women, cyclical perimenstrual flares, oilier skin, jawline distribution) — the androgen-blockade mechanism is specifically relevant; (2) Patients seeking an antiandrogen effect without systemic therapy — clascoterone's topical delivery avoids systemic spironolactone or finasteride effects; (3) Combination therapy layers — adding a unique mechanism to prior topical regimens; (4) Both sexes, 12+ — broadly applicable across the age and sex spectrum relevant to acne. Where established topicals remain preferred: (1) First-line mild acne — retinoids and BP are evidence-rich, affordable, and effective for many patients; (2) Budget-constrained patients — generic topical retinoids, BP, and topical antibiotics are substantially less expensive than Winlevi; (3) Comedogenic acne — retinoids are more directly comedolytic; clascoterone may not be as effective against pure comedonal acne without inflammatory or hormonal features; (4) Established regimens that are working — 'if it ain't broke' applies; no need to switch from an effective retinoid-based regimen just because clascoterone is new. Honest positioning: clascoterone is a valuable addition to the topical acne armamentarium — the first new mechanism in nearly 40 years, genuinely useful for appropriate patients, especially those with androgen-driven acne or those in combination regimens. It is not a dramatic improvement over existing therapies in raw efficacy terms — comparable to retinoids and BP as monotherapy, adding value primarily through mechanism diversification. Most patients benefit from combination therapy (clascoterone + retinoid ± BP) rather than monotherapy replacement of established topicals.
Can clascoterone be used for conditions other than acne and hair loss?
Clascoterone's FDA-approved indication is acne vulgaris 12+; off-label use for hair loss has emerging evidence; other potential androgen-related cutaneous conditions are mechanistically plausible but not supported by rigorous RCT evidence (Trüeb 2021 topical antiandrogen review, PMID: 34318977). Potentially appropriate off-label indications (mechanistically rational, limited evidence): (1) Hidradenitis suppurativa (HS): inflammatory condition of apocrine gland-bearing areas; androgens are implicated in HS pathogenesis; topical clascoterone has theoretical rationale but is not studied in HS RCTs. Some dermatologists may trial clascoterone in mild-moderate HS as part of multi-modal management. (2) Pseudofolliculitis barbae (razor bumps) with androgen component: hair-follicle AR blockade could theoretically reduce beard hair growth and consequent ingrown hair problem; no published trials; theoretical use only. (3) Keratosis pilaris with inflammatory component: some clinicians trial various topicals; clascoterone evidence is absent. (4) Seborrheic dermatitis (modest rationale): seborrhea (oily skin) is a contributing factor; clascoterone's sebum-reducing effect could theoretically help; not studied formally. (5) Acne in specific contexts: post-surgical acne flares, occupational acne mechanica, chloracne (exposure-induced) — theoretical use; no specific evidence. (6) Folliculitis of androgen-dependent type: theoretically responsive to AR blockade; no specific RCT evidence. (7) Female facial hair (hirsutism in specific contexts): theoretically, topical AR blockade could reduce androgen-driven terminal hair growth; currently topical eflornithine (Vaniqa) is the primary topical for this indication; clascoterone's role is speculative. Not appropriate or evidenced for: (1) Rosacea: different pathophysiology (not androgen-driven); do not use clascoterone for rosacea. (2) Psoriasis, eczema, atopic dermatitis: not androgen-driven conditions; clascoterone is not indicated. (3) Skin cancer prevention or treatment: no rationale; not indicated. (4) Anti-aging or cosmetic skin improvement: sebum reduction may be cosmetically desired but is not a medical indication; not positioned as a cosmetic. (5) Treating conditions not specifically studied: off-label dermatology is common but should involve informed discussion with a dermatologist about evidence basis, expectations, and alternatives. Practical framework for off-label use: (1) Maintain realistic expectations — off-label use of clascoterone for non-acne/non-alopecia conditions is extrapolation from the approved indication and mechanism; efficacy may be modest or unpredictable. (2) Specialist involvement — off-label use should involve dermatologist-coordinated care rather than self-directed experimentation. (3) Individual risk-benefit assessment — clascoterone's safety profile is favorable but any off-label use requires weighing against alternative therapies with better evidence. (4) Documentation and follow-up — off-label use should be documented; response assessed; discontinuation if ineffective. Cosmetic and research-only considerations: some patients and researchers have explored clascoterone for cosmetic sebum reduction, bodybuilder/athlete contexts (not legitimate — cosmetic use with no FDA indication), or as part of broader 'bio-hacking' supplement regimens. These uses lack rigorous evidence and should not be confused with evidence-based medical application. Summary: clascoterone's evidence-based role is acne vulgaris (FDA-approved) and emerging androgenetic alopecia (off-label with preliminary evidence). Broader dermatologic applications are possible but largely speculative; stick to evidence-based indications with dermatologist guidance; be skeptical of expansive off-label or cosmetic claims.
Research Tools
Related Compounds
View AllFree 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
